You're one step closer to unlocking our suite of comprehensive and robust tools.
Fill out the form so we can connect you to the right person.
Abbvie to continue manufacturing component for lymphoma drug
Street Talk Episode 52 - A bank's 'knife fight' to stay high performing in a low rate environment
Streaming Media Devices Feel The Squeeze In Q3'19
AT&T To Use Wireless Subs To Create Buzz For HBO
Municipal CUSIP Requests On Pace For Record Year, Thanks To October Issuance Surge
Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.
The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.
Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.